%0 Generic
%A L., Zhao
%A F., Ma
%A Y., Yu
%A Y., Li
%A Y., Wang
%A L., He
%A M., Zhou
%A X., Tian
%A R., Jing
%A L., Li
%A C., Huang
%A M., Bai
%A S., Sun
%D 2019
%T Supplementary Material for: Regional Citrate Anticoagulation versus No-Anticoagulation for Continuous Venovenous Hemofiltration in Acute Severe Hypernatremia Patients with Increased Bleeding Risk: A Retrospective Cohort Study
%U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Regional_Citrate_Anticoagulation_versus_No-Anticoagulation_for_Continuous_Venovenous_Hemofiltration_in_Acute_Severe_Hypernatremia_Patients_with_Increased_Bleeding_Risk_A_Retrospective_Cohort_Study/9821213
%R 10.6084/m9.figshare.9821213.v1
%2 https://karger.figshare.com/ndownloader/files/17616740
%2 https://karger.figshare.com/ndownloader/files/17616743
%2 https://karger.figshare.com/ndownloader/files/17616746
%2 https://karger.figshare.com/ndownloader/files/17616749
%K Acute severe hypernatremia
%K Continuous venovenous hemofiltration
%K Regional citrate anticoagulation
%K No-anticoagulation
%K Increased bleeding risk
%K Serum sodium reduction rate
%X Purpose: This study was aimed at evaluating the efficacy and safety of regional citrate anticoagulation (RCA) versus no-anticoagulation continuous venovenous hemofiltration (CVVH) in acute severe hypernatremia patients with increased bleeding risk. Materials and Methods: Acute severe hypernatremia patients with high bleeding risk who underwent CVVH in our center between January 2011 and October 2017 were considered as candidates. Patients who were <18 years old, with hypovolemic hypernatremia, and had systemic anticoagulation were excluded. The included patients were divided into RCA and no-anticoagulation groups according to their anticoagulation strategy during CVVH and matched by age, sequential organ failure assessment scores, and vasopressor dependency. Results: Of the 64 included patients, no-anticoagulation and RCA were employed for CVVH in 23 and 41 patients, respectively. The serum sodium reduction rate (RRSeNa) was not significantly different between the no-anticoagulation and RCA groups (p = 0.729). Compared to no-anticoagulation, RCA significantly prolonged the circuit survival time (15 h [4.1–23.9] vs. 51 h [21.3–80.7], p = 0.001). The incidence of filter failure was 65.2% (15/23) in the no-anticoagulation group and 2.4% (1/41) in the RCA group (p < 0.001), respectively. In the matched cohort, the RRSeNas were not different between the 2 groups (p = 0.569), and the filter lifespan was significantly longer in the RCA group as well (p < 0.001). Conclusion: RCA might be safe and effective for acute severe hypernatremia patients who underwent CVVH treatment. Further prospective, randomized, control trials are warranted to obtain robust evidences.
%I Karger Publishers